Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

From the plant

CBDVCannabidivarin

The propyl-chain homologue of CBD; one study measured no affinity for human CB1.

Unscheduled
Level of detail

C₁₉H₂₆O₂

CAS 24274-48-4

Family
PhytocannabinoidMinor
Origin
Decarboxylation
Molar mass
286.40 g/mol

Updated on

In plain terms

CBDV is to CBD what THCV is to THC: a version with a shorter side chain, three carbons instead of five. It binds the CB1 receptor only weakly. In a phase 2 clinical trial in adults with epilepsy, it did no better than placebo.

Receptors and activity

Target network

CB2Partial agonistKi = 140 nM · human[3H]CP55,940 displacement, CHO-hCB2 membranes; partial agonism in cAMP inhibition (Emax 51%)
  • Activates
  • Blocks or inhibits

The lower the cited value, the closer the target sits to CBDV: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of CBDV.

Brain, side view
Body, front view
Blood

CB2CB2 found in 5 regions of the body

  1. SpleendenseHighly abundant in the spleen1
  2. Immune cellspresentMainly B cells and natural killer cells1
  3. SkinpresentKeratinocytes, mast cells and nerve fibres2
  4. GutpresentImmune cells of the colonic mucosa3
  5. BonepresentPresent on osteoclasts4

Map sources

  1. Galiègue S et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem, 1995 (new tab)
  2. Ständer S et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci, 2005 (new tab)
  3. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
  4. Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)

Cited values

  1. CB2Partial agonistKi = 140 nM · human48 out of 100

    Zagzoog et al. 2020, Sci Rep (new tab) · [3H]CP55,940 displacement, CHO-hCB2 membranes; partial agonism in cAMP inhibition (Emax 51%)

  2. TRPV1Agonistno measured value cited
  3. GPR55Antagonistno measured value cited
Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of CBDV, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

Cannabidivarin (CBDV) is the propyl-chain (C3) homologue of CBD, described in 1969 in hashish and formed in the plant by decarboxylation of CBDVA. A study on human receptors measured no affinity for CB1 (Ki > 10,000 nM) but binding to CB2 (Ki = 140 nM), with partial agonism (Zagzoog et al. 2020); it also activates and desensitises the TRPV1, TRPV2 and TRPA1 channels (Iannotti et al. 2014). In rodents it had anticonvulsant effects in several models (maximal electroshock and pentylenetetrazole seizures from 100 mg/kg, audiogenic seizures from 50 mg/kg), but no effect on its own on pilocarpine seizures (Hill et al. 2012). In humans, a randomised placebo-controlled phase 2 trial in 162 adults with poorly controlled focal seizures (800 mg twice daily, developed by GW Research under the code GWP42006) showed no difference from placebo in seizure frequency (Brodie et al. 2021).

Key sources.

History

Source
Cannabis sativa L.: present in the plant, formed by non-enzymatic decarboxylation of its acid, CBDVA. Walsh et al. (2021) describe it in landrace varieties rich in CBD and low in Δ9-THC; it is also among the impurities of CBD extracted from hemp inflorescences (Brighenti et al. 2024).

Biosynthetic pathway

CBGVA, the precursor of the propyl cannabinoids, is formed from divarinolic acid; CBDA synthase converts it into CBDVA, a pathway reconstituted in yeast by Luo et al. (2019). CBDV derives from it by decarboxylation under heat, light or time (Walsh et al. 2021).

Classification

Family, origin and source verification

Family

Phytocannabinoid › Minor

Presence in the plant

Neutral form: decarboxylation of a plant acid

Chemistry

Type CBD · C3 side chain · neutral form

Verification

Every fact on this entry was checked against its primary sources on 20 October 2026.

Wikipedia (English)

No dedicated article.

References

  1. Vollner L. et al. 1969, Tetrahedron Lett 10:145-147: cannabidivarin, a new constituent of hashish (new tab)PMID 5778489
  2. Zagzoog A. et al. 2020, Sci Rep 10:20405: pharmacology of minor cannabinoids at human CB1/CB2 (compounds supplied by Aurora Cannabis, co-author) (new tab)PMID 33230154
  3. Iannotti F.A. et al. 2014, ACS Chem Neurosci: CBDV and CBD activate and desensitise TRPV1 (new tab)PMID 25029033
  4. Hill A.J. et al. 2012, Br J Pharmacol 167:1629-1642: cannabidivarin is anticonvulsant in mice and rats (new tab)PMID 22970845
  5. Brodie M.J. et al. 2021, Cannabis Cannabinoid Res 6:528-536: randomised phase 2 trial of CBDV in focal seizures (NCT02365610) (new tab)PMID 33998885
  6. Straiker A. et al. 2021, Molecules 26:5352: CBDV and THCV in two neuronal models (new tab)PMID 34500785
  7. Brighenti V. et al. 2024, Anal Bioanal Chem 416:4555-4569: impurities of natural (CBDV, CBDB) and synthetic CBD (new tab)PMID 38940871

Identifiers

Names

Common name
Cannabidivarin
IUPAC name
2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-propylbenzene-1,3-diol
Other names
Cannabidivarine · Cannabidivarol · GWP42006

Identifiers

Formula
C₁₉H₂₆O₂
CAS
24274-48-4
PubChem CID
11601669(new tab)
ChEBI
CHEBI:182159(new tab)
InChIKey
REOZWEGFPHTFEI-JKSUJKDBSA-N
SMILES
CCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.

In the Journal